These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 37607105)

  • 1. Development and Optimization of A Human Hepatocellular Carcinoma Patient-Derived Organoid Model for Potential Target Identification and Drug Discovery.
    Zhang CY; Zhang XF; Yuan J; Gong YF; Tang H; Guo WY; Li TY; Li CW; Tang YQ; Ma NF; Liu M
    J Vis Exp; 2023 Aug; (198):. PubMed ID: 37607105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human primary liver cancer-derived organoid cultures for disease modeling and drug screening.
    Broutier L; Mastrogiovanni G; Verstegen MM; Francies HE; Gavarró LM; Bradshaw CR; Allen GE; Arnes-Benito R; Sidorova O; Gaspersz MP; Georgakopoulos N; Koo BK; Dietmann S; Davies SE; Praseedom RK; Lieshout R; IJzermans JNM; Wigmore SJ; Saeb-Parsy K; Garnett MJ; van der Laan LJ; Huch M
    Nat Med; 2017 Dec; 23(12):1424-1435. PubMed ID: 29131160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma-derived extracellular matrix for xenofree and cost-effective organoid modeling for hepatocellular carcinoma.
    El-Derby AM; Khedr MA; Ghoneim NI; Gabr MM; Khater SM; El-Badri N
    J Transl Med; 2024 May; 22(1):487. PubMed ID: 38773585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterogeneity, inherent and acquired drug resistance in patient-derived organoid models of primary liver cancer.
    Xian L; Zhao P; Chen X; Wei Z; Ji H; Zhao J; Liu W; Li Z; Liu D; Han X; Qian Y; Dong H; Zhou X; Fan J; Zhu X; Yin J; Tan X; Jiang D; Yu H; Cao G
    Cell Oncol (Dordr); 2022 Oct; 45(5):1019-1036. PubMed ID: 36036881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Organoids as research models for hepatocellular carcinoma.
    Yu JH; Ma S
    Exp Cell Res; 2022 Feb; 411(1):112987. PubMed ID: 34942189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. YAP/TAZ Suppress Drug Penetration Into Hepatocellular Carcinoma Through Stromal Activation.
    Cho K; Ro SW; Lee HW; Moon H; Han S; Kim HR; Ahn SH; Park JY; Kim DY
    Hepatology; 2021 Nov; 74(5):2605-2621. PubMed ID: 34101869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hedgehog signaling promotes sorafenib resistance in hepatocellular carcinoma patient-derived organoids.
    Wang S; Wang Y; Xun X; Zhang C; Xiang X; Cheng Q; Hu S; Li Z; Zhu J
    J Exp Clin Cancer Res; 2020 Jan; 39(1):22. PubMed ID: 31992334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Organoid Models of Human Liver Cancers Derived from Tumor Needle Biopsies.
    Nuciforo S; Fofana I; Matter MS; Blumer T; Calabrese D; Boldanova T; Piscuoglio S; Wieland S; Ringnalda F; Schwank G; Terracciano LM; Ng CKY; Heim MH
    Cell Rep; 2018 Jul; 24(5):1363-1376. PubMed ID: 30067989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer-Associated Fibroblasts Provide a Stromal Niche for Liver Cancer Organoids That Confers Trophic Effects and Therapy Resistance.
    Liu J; Li P; Wang L; Li M; Ge Z; Noordam L; Lieshout R; Verstegen MMA; Ma B; Su J; Yang Q; Zhang R; Zhou G; Carrascosa LC; Sprengers D; IJzermans JNM; Smits R; Kwekkeboom J; van der Laan LJW; Peppelenbosch MP; Pan Q; Cao W
    Cell Mol Gastroenterol Hepatol; 2021; 11(2):407-431. PubMed ID: 32932015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-derived multicellular tumor spheroids towards optimized treatment for patients with hepatocellular carcinoma.
    Song Y; Kim JS; Kim SH; Park YK; Yu E; Kim KH; Seo EJ; Oh HB; Lee HC; Kim KM; Seo HR
    J Exp Clin Cancer Res; 2018 May; 37(1):109. PubMed ID: 29801504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthetic lethality: A promising therapeutic strategy for hepatocellular carcinoma.
    Tang L; Chen R; Xu X
    Cancer Lett; 2020 Apr; 476():120-128. PubMed ID: 32070778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The phosphatidylethanolamine biosynthesis pathway provides a new target for cancer chemotherapy.
    Guan Y; Chen X; Wu M; Zhu W; Arslan A; Takeda S; Nguyen MH; Majeti R; Thomas D; Zheng M; Peltz G
    J Hepatol; 2020 Apr; 72(4):746-760. PubMed ID: 31760071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Updates on Organoid Model for the Study of Liver Cancer.
    El-Khobar KE; Sukowati CHC
    Technol Cancer Res Treat; 2023; 22():15330338231154090. PubMed ID: 36788421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current discovery strategies for hepatocellular carcinoma therapeutics.
    Dai Q; Zhang C; Yuan Z; Sun Q; Jiang Y
    Expert Opin Drug Discov; 2020 Feb; 15(2):243-258. PubMed ID: 31809618
    [No Abstract]   [Full Text] [Related]  

  • 15. Identification and functional characterization of potential oncofetal targets in human hepatocellular carcinoma.
    Li MM; Kong FE; Li GM; He YT; Zhang XF; Zhang CY; Liang JK; Guan XY; Ma NF; Xie MB; Liu M
    STAR Protoc; 2022 Dec; 3(4):101921. PubMed ID: 36595904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comprehensive study of epigenetic alterations in hepatocellular carcinoma identifies potential therapeutic targets.
    Bayo J; Fiore EJ; Dominguez LM; Real A; Malvicini M; Rizzo M; Atorrasagasti C; García MG; Argemi J; Martinez ED; Mazzolini GD
    J Hepatol; 2019 Jul; 71(1):78-90. PubMed ID: 30880225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
    Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
    J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microenvironment of a tumor-organoid system enhances hepatocellular carcinoma malignancy-related hallmarks.
    Wang Y; Takeishi K; Li Z; Cervantes-Alvarez E; Collin de l'Hortet A; Guzman-Lepe J; Cui X; Zhu J
    Organogenesis; 2017 Jul; 13(3):83-94. PubMed ID: 28548903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver Organoids as an In Vitro Model to Study Primary Liver Cancer.
    De Siervi S; Turato C
    Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of matched patient-derived xenograft in vitro-in vivo models using 3D macroporous hydrogels for the study of liver cancer.
    Fong ELS; Toh TB; Lin QXX; Liu Z; Hooi L; Mohd Abdul Rashid MB; Benoukraf T; Chow EK; Huynh TH; Yu H
    Biomaterials; 2018 Mar; 159():229-240. PubMed ID: 29353739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.